3D pathological tissue images have a richer amount of information than traditional 2D, which can assist doctors in diagnosis. In the past, the reason why pathological tissues were difficult to 3D was because the imaging method of pathological tissues had to be sliced into thin slices, and then the sliced samples on the glass slides were observed with a microscope.

Through the clarification technology of technical transfer, Jello Biotechnology can scan with a laser microscope to create a three-dimensional tissue structure without damaging the tissue. With appropriate staining techniques, doctors can see the cell structure in the tissues, and even the distribution of cancer genes. In addition, Jello Biotech reuses AI technology for image analysis, which can calculate the number of different cells and provide them for physicians' reference.

At present, Jello Biotechnology can provide physicians with computer AI intelligence to analyze and compare the 3D characteristics of specimens, see 100 times more tissue details, and assist pathologists in making better clinical decisions.

Looking forward to the future, Jello Biotech will further obtain LDTS laboratory certification (referring to the medical laboratory’s own research, development, manufacturing, and verified processes) to provide medical-grade clinical testing products and services. It is planned to cut into the $1 billion standard. Target inspection market opportunities.